Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia
On Aug. 19, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted accelerated…